Overview

Programmed cell death 1 ligand 2 (PDCD1LG2; also known as PDL2) is a gene that encodes a protein that functions in the costimulatory signal that is required for T-cell proliferation and IFNG production. The interaction of the protein with PDCD1 blocks T-cell proliferation. Fusions, missense mutations, silent mutations, and frameshift deletions are observed in cancers such as intestinal cancer, skin cancer, and stomach cancer.

PDCD1LG2 is altered in 0.83% of all cancers with lung adenocarcinoma, breast invasive ductal carcinoma, colon adenocarcinoma, bladder urothelial carcinoma, and high grade ovarian serous adenocarcinoma having the greatest prevalence of alterations [3].

The most common alterations in PDCD1LG2 are PDCD1LG2 Amplification (0.29%), PDCD1LG2 Loss (0.25%), PDCD1LG2 P81S (0.08%), PDCD1LG2 Q144L (0.04%), and PDCD1LG2 X273_splice (0.16%) [3].

Significance of PDCD1LG2 in Diseases

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.